The milestone date of 17 January 2022 for the treatment of COVID-19 in Cyprus with the medicinal product Molnupiravir 200mg hard capsules already available to both physicians and beneficiaries of the General Health System, citizens.
Presenting the profile of the pharmaceutical formulation, the Deputy Director of Pharmaceutical Services, Elena Panagiotopoulou said that it is indicated for people over 65 years old and not under 18 and can be administered to special categories of vulnerable groups of the population.
She added that adverse reactions after its administration are not of concern and concern mild dizziness, headache and intestinal disorders and noted that in February public health services will have the PFIZER drug available.
(CNA)
CNA - Argyro Angelidou
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
